ESR1 and breast carcinoma: Ma et al. performed gene expression profiling in the cohort of 60 women receiving adjuvant tamoxifen alone in an early stage estrogen receptor positive breast cancer patient cohort, and found a significant difference of CHDH in genes between tamoxifen treated breast cancer patients who relapsed and did not relapse (Ma et al., 2004).